vial of retatrutide Retatrutide: Evidence, Safety & Options GLP-3 Retatrutide (24mg vials) -

Plateaus are normal and do not indicate treatment failure

The 24.2% reduction at 48 weeks exceeds tirzepatide results that took 72 weeks to achieve 22.5%, and far surpasses semaglutide results of 14.9% at 68 weeks

Bezin J, Gouverneur A, Penichon M, Mathieu C, Garrel R, Hillaire-Buys D, et al

As Comorbidities Rise, GLP-1s Gain Ground Beyond Diabetes and Obesity Among the many conditions that frequently overlap with T2D and obesity, obstructive sleep apnea (OSA), MASHa subset of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), hypertension, and high cholesterol are among the most prevalent

For people using insulin or sulfonylureas alongside retatrutide , the risk of hypoglycaemia may increase as blood glucose improves

Common side effects are typically mild and manageable, while serious adverse events remain rare